Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: A pilot study

Noriaki Iwao, Minoru Yoshida, Kiyohiko Hatake, Yoshiaki Hoshino, Shoutaro Hagiwara, Hiroshi Tomizuka, Ritsuko Shimizu, Toshiyuki Suzuki, Yusuke Furukawa, Norio Komatsu, Kazuo Muroi, Akiyoshi Miwa, Shinobu Sakamoto, Yasusada Miura

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Fourteen patients with high-risk leukemia (six with relapsed AML, three with relapsed ALL, one with AML-M0, four with CML in myeloid blastic crisis) were treated with a combination chemotherapy of carboplatin (200-300 mg/m2/day) and cytosine arabinoside (100 mg/m2/day) by 24 h continuous infusion for 5-7 days. Five patients (35.7%) achieved complete remission including two patients complicated with myelofibrosis (one with AML-M0 and one with CML in myelo-megakaryocytic crisis). Thirteen patients had nausea and vomiting, five patients had severe, prolonged neutropenia for which it was necessary to administer granulocyte colony-stimulating factor and six patients had severe thrombocytopenia. We concluded that this regimen is effective for the treatment of high-risk leukemia.

Original languageEnglish
Pages (from-to)899-903
Number of pages5
JournalLeukemia Research
Volume19
Issue number12
DOIs
Publication statusPublished - 1995 Dec
Externally publishedYes

Keywords

  • Carboplatin
  • continuous infusion
  • cytosine arabinoside
  • high-risk leukemia
  • prolonged neutropenia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: A pilot study'. Together they form a unique fingerprint.

Cite this